The biology of HDAC in cancer: The nuclear and epigenetic components

Handbook of Experimental Pharmacology

Volumn 206, Issue , 2011, Pages 13-37

  Hagelkruys, Astrid ^a   Sawicka, Anna ^a   Rennmayr, Magdalena ^a   Seiser, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Epigenetic therapy; Hallmarks of cancer; Malignancies; Tumorigenesis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; ROMIDEPSIN; SIRTUIN 1; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GENETICS; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DEVELOPMENTAL BIOLOGY; DIGESTIVE SYSTEM CANCER; EPIGENETICS; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; NEUROBLASTOMA; NONHUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN FAMILY; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 80054720150     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-21631-2_2     Document Type: Article

References (139)

1. Adams H, Fritzsche FR, Dirnhofer S, Kristiansen G, Tzankov A (2010) Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opin Ther Targets 14(6):577-584
2. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW (2001) ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21(19):6470-6483 (Pubitemid 32927415)
3. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2(6):420-430 (Pubitemid 37328939)
4. Atsumi A, Tomita A, Kiyoi H, Naoe T (2006) Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun 345(4):1471-1480 (Pubitemid 43817898)
5. Bartl S, Taplick J, Lagger G, Khier H, Kuchler K, Seiser C (1997) Identification of mouse histone deacetylase 1 as a growth factor-inducible gene. Mol Cell Biol 17(9):5033-5043 (Pubitemid 27357602)
6. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401-410 (Pubitemid 37328844)
7. Beumer JH, Tawbi H (2010) Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 5(3):196-208
8. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW (2008) Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 30(1):61-72 (Pubitemid 351470157)
9. Bicaku E, Marchion DC, Schmitt ML, Munster PN (2008) Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 68(5):1513-1519 (Pubitemid 351346860)
10. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21(1):103-107 (Pubitemid 29036293)
11. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438(7070):932-936 (Pubitemid 43093958)
12. Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, Fan PL, Hsiao PW (2009) Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 15(3):840-850.
13. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24(19):8467-8476 (Pubitemid 39245069)
14. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN (2006) Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126(2):321-334 (Pubitemid 44092958)
15. Chauchereau A, Mathieu M, de Saintignon J, Ferreira R, Pritchard LL, Mishal Z, Dejean A, Harel-Bellan A (2004) HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. Oncogene 23(54):8777-8784 (Pubitemid 39593292)
16. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW, KF (2003) Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)- deficient mice. Proc Natl Acad Sci USA 100(19):10794-10799 (Pubitemid 37140107)
17. Cho HH, Park HT, Kim YJ, Bae YC, Suh KT, Jung JS (2005) Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J Cell Biochem 96(3):533-542 (Pubitemid 41504651)
18. Chou CW, Chen CC (2008) HDAC inhibition upregulates the expression of angiostatic ADAMTS1. FEBS Lett 582(29):4059-4065
19. Christofori G, Semb H (1999) The role of the cell-adhesion molecule E-cadherin as a tumoursuppressor gene. Trends Biochem Sci 24(2):73-76 (Pubitemid 29346577)
20. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305(5682):390-392 (Pubitemid 38938153)
21. Deltour S, Guerardel C, Leprince D (1999) Recruitment of SMRT/N-CoR-mSin3A-HDACrepressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B. Proc Natl Acad Sci USA 96(26):14831-14836 (Pubitemid 30019725)
22. Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280(2):145-153
23. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 3(4):e2020
24. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 13(16):4882-4890 (Pubitemid 47294796)
25. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1):27-31
26. Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339(6219):58-61 (Pubitemid 19115892)
27. Ford J, Jiang M, Milner J (2005) Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65(22):10457-10463 (Pubitemid 41743740)
28. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37(4):391-400
29. Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid RM, Saur D, Schneider G (2009) HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 58(10):1399-1409
30. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK (2003) Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310(2):529-536 (Pubitemid 37163696)
31. Grausenburger R, Bilic I, Boucheron N, Zupkovitz G, El-Housseiny L, Tschismarov R, Zhang Y, Rembold M, Gaisberger M, Hartl A, Epstein MM, Matthias P, Seiser C, Ellmeier W (2010) Conditional deletion of HDAC1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol 185(6):3489-3497
32. Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN (2009a) Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci USA 106(19):7751-7755
33. Haberland M, Mokalled MH, Montgomery RL, Olson EN (2009b) Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 23(14):1625-1630
34. Haberland M, Montgomery RL, Olson EN (2009c) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10(1):32-42
35. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59(2):177-189 (Pubitemid 38481229)
36. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70 (Pubitemid 30046295)
37. Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T (2010) Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer 127(6):1332-1346
38. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, Depinho RA, Gu Y, Simon JA, Bedalov A (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66(8):4368-4377
39. Hirokawa Y, Arnold M, Nakajima H, Zalcberg J, Maruta H (2005) Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifenresistance. Cancer Biol Ther 4(9):956-960 (Pubitemid 41598590)
40. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K, Denk H (2006) Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5(9):2203-2210 (Pubitemid 44530456)
41. Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH (2004) Histone deacetylase inhibitionmediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci USA 101(47):16659-16664 (Pubitemid 39557769)
42. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12(4):395-404 (Pubitemid 40520691)
43. Inoue S, Mai A, Dyer MJ, Cohen GM (2006) Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosisinducing ligand-induced apoptosis. Cancer Res 66(13):6785-6792 (Pubitemid 44085638)
44. Jin KL, Pak JH, Park JY, Choi WH, Lee JY, Kim JH, Nam JH (2008) Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol 19(3):185-190
45. Kato H, Tamamizu-Kato S, Shibasaki F (2004) Histone deacetylase 7 associates with hypoxiainducible factor 1alpha and increases transcriptional activity. J Biol Chem 279(40):41966-41974 (Pubitemid 39313647)
46. Ke Q, Costa M (2006) Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70(5):1469-1480.
47. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2(10):727-739 (Pubitemid 37328908)
48. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP (2007) Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 99(14):1107-1119 (Pubitemid 47241395)
49. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, Rice VM (2007) Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther 6(5):795-801 (Pubitemid 47328364)
50. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7(4):437-443 (Pubitemid 32298546)
51. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH, Kim DY (2004) Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 19(2):218-224
52. Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C, Chen C, Chung CH, Huber O, Rose DW, Sawyers CL, Rosenfeld MG, Baek SH (2005) Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 434(7035):921-926 (Pubitemid 40559007)
53. Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, Jung BK, Bae MK, Kim KW (2007) Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 17(3):647-651
54. Kramer OH (2009) HDAC2: a critical factor in health and disease. Trends Pharmacol Sci 30(12):647-655
55. Krebs JE, Fry CJ, Samuels ML, Peterson CL (2000) Global role for chromatin remodeling enzymes in mitotic gene expression. Cell 102(5):587-598
56. Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM, Alfer J (2005) Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 90(1):15-23 (Pubitemid 40486997)
57. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21(11):2672-2681 (Pubitemid 34619383)
58. Lagger S, Meunier D, Mikula M, Brunmeir R, Schlederer M, Artaker M, Pusch O, Egger G, Hagelkruys A, Mikulits W, Weitzer G, Muellner EW, Susani M, Kenner L, Seiser C (2010) Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J 29(23):3992-4007
59. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ (2008) Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13(5):454-463 (Pubitemid 351609441)
60. Leder A, Orkin S, Leder P (1975) Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis. Science 190(4217):893-894
61. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, Yao TP (2008) The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 68(18):7561-7569
62. Lee KJ, Lee KY, Lee YM (2010) Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1alpha to reverse HRE site in the promoter. Biochim Biophys Acta 1803(5):608-616
63. Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J, Phelan C, Lazar MA (2006) A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev 20(18):2566-2579 (Pubitemid 44396841)
64. Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY, Iraci N, Sekyere E, Haber M, Norris MD, Diolaiti D, Della Valle G, Perini G, Marshall GM (2007) Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci USA 104(47):18682-18687 (Pubitemid 350210757)
65. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107(2):137-148 (Pubitemid 33035941)
66. Ma X, Ezzeldin HH, Diasio RB (2009) Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69(14):1911-1934
67. MacDonald JL, Roskams AJ (2008) Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development. Dev Dyn 237(8):2256-2267
68. Madhusudan S, Harris AL (2002) Drug inhibition of angiogenesis. Curr Opin Pharmacol 2(4):403-414 (Pubitemid 34830971)
69. Mal A, Sturniolo M, Schiltz RL, Ghosh MK, Harter ML (2001) A role for histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD: inhibition of the myogenic program. EMBO J 20(7):1739-1753 (Pubitemid 32299410)
70. Marquard L, Poulsen CB, Gjerdrum LM, de Nully BP, Christensen IJ, Jensen PB, Sehested M, Johansen P, Ralfkiaer E (2009) Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 54(6):688-698
71. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, Chang DK, Liu PY, Jankowski K, Iraci N, Haber M, Norris MD, Keating J, Sekyere E, Jonquieres G, Stossi F, Katzenellenbogen BS, Biankin AV, Perini G, Liu T (2010) Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29(44):5957-5968
72. Mazieres J, Tovar D, He B, Nieto-Acosta J, Marty-Detraves C, Clanet C, Pradines A, Jablons D, Favre G (2007) Epigenetic regulation of RhoB loss of expression in lung cancer. BMC Cancer 7:220
73. McBurney MW, Yang X, Jardine K, Hixon M, Boekelheide K, Webb JR, Lansdorp PM, Lemieux M (2003) The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol 23(1):38-54 (Pubitemid 36008499)
74. Mercurio C, Minucci S, Pelicci PG (2010) Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 62(1):18-34
75. Minucci S, Nervi C, Lo Coco F, Pelicci PG (2001) Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20(24):3110-3115 (Pubitemid 32553566)
76. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101 (10):4055-4062 (Pubitemid 36857886)
77. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, Morine Y, Shimada M (2008) Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasisassociated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36(3):e1-e9 (Pubitemid 351440946)
78. Moehler TM, Neben K, Ho AD, Goldschmidt H (2001) Angiogenesis in hematologic malignancies. Ann Hematol 80(12):695-705 (Pubitemid 34041426)
79. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, Olson EN (2007) Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 21(14):1790-1802 (Pubitemid 47076478)
80. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Humphries KM, Richardson JA, Bassel-Duby R, Olson EN (2008) Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 118(11):3588-3597
81. Montgomery RL, Hsieh J, Barbosa AC, Richardson JA, Olson EN (2009) Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc Natl Acad Sci USA 106(19):7876-7881
82. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S, Murphy MM, Mills KD, Patel P, Hsu JT, Hong AL, Ford E, Cheng HL, Kennedy C, Nunez N, Bronson R, Frendewey D, Auerbach W, Valenzuela D, Karow M, Hottiger MO, Hursting S, Barrett JC, Guarente L, Mulligan R, Demple B, Yancopoulos GD, Alt FW (2006) Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124(2): 315-329 (Pubitemid 43121980)
83. Mottet D, Bellahcene A, Pirotte S, Waltregny D, Deroanne C, Lamour V, Lidereau R, Castronovo V (2007) Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res 101(12):1237-1246 (Pubitemid 350294640)
84. Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A, Bellahcene A, Verdin E, Castronovo V (2009) HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 28(2):243-256
85. Moustakas A, Heldin CH (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98(10):1512-1520 (Pubitemid 47308444)
86. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61(23):8492-8497 (Pubitemid 33131130)
87. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, Tsuneyoshi M (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18(4):769-774
88. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28(14):1714-1724
89. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O (2009) Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15(1):91-99
90. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T (2004) Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 112(1):26-32 (Pubitemid 39249488)
91. Osborne CK, Yochmowitz MG, Knight WA 3rd, McGuire WL (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46(12 Suppl):2884-2888 (Pubitemid 11205652)
92. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y, Kaneki M (2006) Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras- MAPK signaling in human cancer cells. Oncogene 25(2):176-185 (Pubitemid 43083679)
93. Ouaissi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, Lafontaine JS, Payan MJ, Dahan L, Pirro N, Seitz JF, Mas E, Lombardo D, Ouaissi A (2008) High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 15(8):2318-2328
94. Pasqualucci L, Bereschenko O, Niu H, Klein U, Basso K, Guglielmino R, Cattoretti G, Dalla-Favera R (2003) Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk Lymphoma 44(Suppl 3):S5-S12 (Pubitemid 38196057)
95. Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415-428 (Pubitemid 46809165)
96. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler- Stevenson M, Lade S, Fojo AT, Bates SE (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27(32):5410-5417
97. Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H (2007) The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res 142(2):219-226 (Pubitemid 47418819)
98. Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H (2008) Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res 148(1):31-37
99. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66(17):8814-8821 (Pubitemid 44449199)
100. Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, Mandawat A, Atadja P, Bradner JE, Bhalla K (2008) HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 112(5):1886-1893
101. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95(6):3003-3007 (Pubitemid 28135844)
102. Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1(1):19-25 (Pubitemid 46776612)
103. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, Caballero R, Alaminos M, Setien F, Paz MF, Herranz M, Palacios J, Arango D, Orntoft TF, Aaltonen LA, Schwartz S Jr, Esteller M (2006) A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38(5):566-569
104. Schuler S, Fritsche P, Diersch S, Arlt A, Schmid RM, Saur D, Schneider G (2010) HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer 9:80.
105. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S (2007) Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27(13):4784-4795 (Pubitemid 47016131)
106. Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE (2005) Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 19(7):1740-1751 (Pubitemid 41007887)
107. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, Nam SW (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113(4):264-268 (Pubitemid 40676807)
108. Svechnikova I, Almqvist PM, Ekstrom TJ (2008) HDAC inhibitors effectively induce cell typespecific differentiation in human glioblastoma cell lines of different origin. Int J Oncol 32(4):821-827 (Pubitemid 351780592)
109. Tanaka M, Levy J, Terada M, Breslow R, Rifkind RA, Marks PA (1975) Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. Proc Natl Acad Sci USA 72(3):1003-1006
110. Tenen DG (2003) Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3(2):89-101 (Pubitemid 37328876)
111. Thomas S, Munster PN (2009) Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett 280(2):184-191
112. Tou L, Liu Q, Shivdasani RA (2004) Regulation of mammalian epithelial differentiation and intestine development by class I histone deacetylases. Mol Cell Biol 24(8):3132-3139 (Pubitemid 38452059)
113. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, Ferrari VA, Abrams CS, Gruber PJ, Epstein JA (2007) Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 13(3):324-331 (Pubitemid 46376684)
114. Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, Braun T, Bober E (2008) Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 102(6):703-710 (Pubitemid 351457857)
115. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107(2):149-159 (Pubitemid 33035942)
116. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119(4):555-566 (Pubitemid 39482354)
117. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, Schnieke A, Schmid RM, Schneider G, Saur D (2009) E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 137(1):361-371, e361-e365
118. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM (1998) ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/ HDAC1 complex. Proc Natl Acad Sci USA 95(18):10860-10865 (Pubitemid 28413159)
119. Wang FX, Dong ZR, Liu ZL, Pan L, Luo JM, Zhang XJ, Hao HL, Li XL, Yang JC, Jiang LL (2004) Mitochondrial ceramidase overexpression up-regulates Bcl-2 protein level in K562 cells, probably through its metabolite sphingosine-1-phosphate. Zhongguo Shi Yan Xue Ye Xue Za Zhi 12(5):577-583
120. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Jia R, Zheng ZM, Appella E, Wang XW, Ried T, Deng CX (2008) Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14(4):312-323
121. Weichert W (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280(2):168-176
122. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G (2008a) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98(3):604-610 (Pubitemid 351214528)
123. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C (2008b) Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 14(6):1669-1677 (Pubitemid 351469450)
124. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281(19):13548-13558 (Pubitemid 43855268)
125. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, Mariadason JM (2008) HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 19(10):4062-4075
126. Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J, DePinho RA, Dannenberg JH (2010) Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J 29(15):2586-2597
127. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37):5541-5552 (Pubitemid 47255934)
128. Yamaguchi T, Cubizolles F, Zhang Y, Reichert N, Kohler H, Seiser C, Matthias P (2010) Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev 24(5):455-469
129. Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, Sugimachi K (2003) Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 103(5):572-576 (Pubitemid 36091459)
130. Yoo EJ, Chung JJ, Choe SS, Kim KH, Kim JB (2006) Down-regulation of histone deacetylases stimulates adipocyte differentiation. J Biol Chem 281(10):6608-6615
131. Yuan J, Minter-Dykhouse K, Lou Z (2009) A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 185(2):203-211
132. Yuan GB, Kuang AR, Fan Q, Yu LB, Mi YX (2010) Combined effects of all-trans-retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells. Chin J Cancer 29(4):379-384
133. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110(4):479-488 (Pubitemid 35232291)
134. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H (2005) Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast * Breast Cancer Res Treat 94(1):11-16 (Pubitemid 41416937)
135. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, Lombard D, Mizeracki A, Matthias G, Alt FW, Khochbin
136. Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, Wu M, Pan Z, Zhou W (2010) microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 103(8):1215-1220
137. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5(5):455-463 (Pubitemid 38610247)
138. Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K, Egger G, Grausenburger R, Schweifer N, Chiocca S, Decker T, Seiser C (2006) Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol 26(21):7913-7928 (Pubitemid 44630992)
139. Zupkovitz G, Grausenburger R, Brunmeir R, Senese S, Tischler J, Jurkin J, Rembold M, Meunier D, Egger G, Lagger S, Chiocca S, Propst F, Weitzer G, Seiser C (2010) The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol 30(5):1171-1181